clinical trial · NCT03939026
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
Relapsed/Refractory Large B Cell LymphomaRelapsed/Refractory Follicular LymphomaALLO-501ALLO-647FludarabineCyclophosphamide
brief summary
The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
started
May 1, 2019
primary completion
Oct 23, 2021
completion
Jan 28, 2025
last updated
Mar 2, 2026
official title
A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory Large B-Cell Lymphoma or Follicular Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol